Etirinotecan pegol
Etirinotecan pegol (trade name Onzeald) is a drug developed by Nektar Therapeutics for the treatment of certain kinds of breast cancer with brain metastases. The European Medicines Agency refused to grant it a marketing authorisation in 2017.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Etirinotecan pegol
Etirinotecan pegol (trade name Onzeald) is a drug developed by Nektar Therapeutics for the treatment of certain kinds of breast cancer with brain metastases. The European Medicines Agency refused to grant it a marketing authorisation in 2017.
has abstract
Etirinotecan pegol (trade name ...... 1.2 units of trifluoroacetate.
@en
alternative name
Onzeald
@en
CAS number
848779-32-8
chemical formula
C153H176N20O36[C8H16O4]n (n≈113)
DrugBank
FDA UNII code
LJ16641SFT
KEGG
Wikipage page ID
50,977,253
page length (characters) of wiki page
Wikipage revision ID
1,008,942,318
Link from a Wikipage to another Wikipage
ATC prefix
L01
@en
ATC suffix
CE03
@en
CAS number
chemical formula
C153H176N20O36[C8H16O4]n
@en
DrugBank
DB14951
@en
elimination half-life
3283200.0
excretion
mostly via kidneys
@en
KEGG
D10367
@en
metabolites
irinotecan and its metabolites
@en
molecular weight
protein bound
none
@en
routes of administration
synonyms
NKTR-102
@en
tradename
Onzeald
@en
UNII
LJ16641SFT
@en
wikiPageUsesTemplate
subject
comment
Etirinotecan pegol (trade name ...... rketing authorisation in 2017.
@en
label
Etirinotecan pegol
@en